Kymera readout hints at new era for degraders in immunology

Kymera has taken the next step toward its goal of bringing oral drugs with biologics-like activity to autoimmune disease patients with a Phase Ib readout in atopic dermatitis that sent its shares up 42% Monday. Though early stage, the biomarker data suggest the STAT6 degrader is already in Dupixent-like territory on key indicators of Type 2 inflammation after four weeks of treatment.

Pharma interest in STAT6 has been growing, but Kymera’s degrader remains unpartnered...